Fulltext

Infusional ECarboF in patients with advanced breast cancer: A very active and well-tolerated out-patient regimen

Hügli, A. ; Sappino, A.-P ; Anchisi, S. ; Mermillod, B. ; Schafer, P. ; Anguenot, J. L. ; Bonnefoi, H.

In: Annals of Oncology, 2000, vol. 11, no. 12, p. 1557-1561

Ajouter à la liste personnelle
    Titre
    • Infusional ECarboF in patients with advanced breast cancer: A very active and well-tolerated out-patient regimen
    Auteur
    • Hügli, A.. Division d'Oncologie, Hôpital Cantonal Universitaire de Genève Switzerland
    • Sappino, A.-P. Division d'Oncologie, Hôpital Cantonal Universitaire de Genève Switzerland
    • Anchisi, S.. Service d'Oncologie, Hôpital Régional de Sion Switzerland
    • Mermillod, B.. Division d'Informatique Médicale, Hôpital Cantonal Universitaire de Genève Switzerland
    • Schafer, P.. Département de Gynécologie-Obstétrique, Hôpital Cantonal Universitaire de Genève Switzerland
    • Anguenot, J. L.. Département de Gynécologie-Obstétrique, Hôpital Cantonal Universitaire de Genève Switzerland
    • Bonnefoi, H.. Département de Gynécologie-Obstétrique, Hôpital Cantonal Universitaire de Genève Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2000, vol. 11, no. 12, p. 1557-1561. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:302895
    Summary
    We performed a trial using the combination of epirubicin 50 mg/m2/day 1, carboplatinum AUC 5/day 1 and continuous 5-fluorouracil (5-FU) 200 mg/m2/day (every 4 weeks for 6 months) to confirm the efficacy and low toxicity profile of this regimen in breast cancer. In 51 patients with metastatic (n = 33) or locally advanced (n=18) breast cancer the overall response rate was 86% (95% confidence interval (95% CI): 73%-94%): 94% in locally advanced and 81% metastatic disease. Grade 3-4 toxicity was low: 4% of patients presented with febrile neutropenia, 16% with severe palmar-plantar syndrome, 10% with Port-a-cath thrombosis. This study confirms the high efficacy of infusional 5-FU-based regimens and justifies further research into novel promising oral 5-FU derivatives